Dopaminergic Activity in Antipsychotic-Naïve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response

Research output: Contribution to journalJournal articlepeer-review

Standard

Dopaminergic Activity in Antipsychotic-Naïve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment : Association With Psychotic Symptoms and Treatment Response. / Sigvard, Anne Korning; Nielsen, Mette Ødegaard; Gjedde, Albert; Bojesen, Kirsten Borup; Fuglø, Dan; Tangmose, Karen; Kumakura, Yoshitaka; Heltø, Kim; Ebdrup, Bjørn H.; Jensen, Lars Thorbjørn; Rostrup, Egill; Glenthøj, Birte Yding.

In: Biological Psychiatry, Vol. 91, No. 2, 2022, p. 236-245.

Research output: Contribution to journalJournal articlepeer-review

Harvard

Sigvard, AK, Nielsen, MØ, Gjedde, A, Bojesen, KB, Fuglø, D, Tangmose, K, Kumakura, Y, Heltø, K, Ebdrup, BH, Jensen, LT, Rostrup, E & Glenthøj, BY 2022, 'Dopaminergic Activity in Antipsychotic-Naïve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response', Biological Psychiatry, vol. 91, no. 2, pp. 236-245. https://doi.org/10.1016/j.biopsych.2021.08.023

APA

Sigvard, A. K., Nielsen, M. Ø., Gjedde, A., Bojesen, K. B., Fuglø, D., Tangmose, K., Kumakura, Y., Heltø, K., Ebdrup, B. H., Jensen, L. T., Rostrup, E., & Glenthøj, B. Y. (2022). Dopaminergic Activity in Antipsychotic-Naïve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response. Biological Psychiatry, 91(2), 236-245. https://doi.org/10.1016/j.biopsych.2021.08.023

Vancouver

Sigvard AK, Nielsen MØ, Gjedde A, Bojesen KB, Fuglø D, Tangmose K et al. Dopaminergic Activity in Antipsychotic-Naïve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response. Biological Psychiatry. 2022;91(2):236-245. https://doi.org/10.1016/j.biopsych.2021.08.023

Author

Sigvard, Anne Korning ; Nielsen, Mette Ødegaard ; Gjedde, Albert ; Bojesen, Kirsten Borup ; Fuglø, Dan ; Tangmose, Karen ; Kumakura, Yoshitaka ; Heltø, Kim ; Ebdrup, Bjørn H. ; Jensen, Lars Thorbjørn ; Rostrup, Egill ; Glenthøj, Birte Yding. / Dopaminergic Activity in Antipsychotic-Naïve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment : Association With Psychotic Symptoms and Treatment Response. In: Biological Psychiatry. 2022 ; Vol. 91, No. 2. pp. 236-245.

Bibtex

@article{ffcf73486f1c416588435e79364303cb,
title = "Dopaminergic Activity in Antipsychotic-Na{\"i}ve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment: Association With Psychotic Symptoms and Treatment Response",
abstract = "Background: Dopamine activity has been associated with the response to antipsychotic treatment. Our study used a four-parameter model to test the association between the striatal decarboxylation rate of 18F-DOPA to 18F-dopamine (k3) and the effect of treatment on psychotic symptoms in antipsychotic-na{\"i}ve patients with first-episode psychosis. We further explored the effect of treatment with a partial dopamine D2 receptor agonist (aripiprazole) on k3 and dopamine synthesis capacity (DSC) determined by the four-parameter model and by the conventional tissue reference method. Methods: Sixty-two individuals (31 patients and 31 control subjects) underwent 18F-DOPA positron emission tomography at baseline, and 15 patients were re-examined after 6 weeks. Clinical re-examinations were completed after 6 weeks (n = 28) and 6 months (n = 15). Symptoms were evaluated with the Positive and Negative Syndrome Scale. Results: High baseline decarboxylation rates (k3) were associated with more positive symptoms at baseline (p < .001) and with symptom improvement after 6 weeks (p = .006). Subregion analyses showed that baseline k3 for the putamen (p = .003) and nucleus accumbens (p = .013) and DSC values for the nucleus accumbens (p = .003) were associated with psychotic symptoms. The tissue reference method yielded no associations between DSC and symptoms or symptom improvement. Neither method revealed any effects of group or treatment on average magnitudes of k3 or DSC, whereas changes in dopamine synthesis were correlated with higher baseline values, implying a potential effect of treatment. Conclusions: Striatal decarboxylation rate at baseline was associated with psychotic symptoms and treatment response. The strong association between k3 and treatment effect potentially implicate on new treatment strategies.",
keywords = "Antipsychotic-na{\"i}ve schizophrenia, Aripiprazole, Dopa decarboxylase, dopamine, Dopamine, F-DOPA, Partial agonist, Positron emission tomography, Psychosis, Striatum, Treatment outcome",
author = "Sigvard, {Anne Korning} and Nielsen, {Mette {\O}degaard} and Albert Gjedde and Bojesen, {Kirsten Borup} and Dan Fugl{\o} and Karen Tangmose and Yoshitaka Kumakura and Kim Helt{\o} and Ebdrup, {Bj{\o}rn H.} and Jensen, {Lars Thorbj{\o}rn} and Egill Rostrup and Glenth{\o}j, {Birte Yding}",
note = "Publisher Copyright: {\textcopyright} 2021 Society of Biological Psychiatry",
year = "2022",
doi = "10.1016/j.biopsych.2021.08.023",
language = "English",
volume = "91",
pages = "236--245",
journal = "Biological Psychiatry",
issn = "0006-3223",
publisher = "Elsevier",
number = "2",

}

RIS

TY - JOUR

T1 - Dopaminergic Activity in Antipsychotic-Naïve Patients Assessed With Positron Emission Tomography Before and After Partial Dopamine D2 Receptor Agonist Treatment

T2 - Association With Psychotic Symptoms and Treatment Response

AU - Sigvard, Anne Korning

AU - Nielsen, Mette Ødegaard

AU - Gjedde, Albert

AU - Bojesen, Kirsten Borup

AU - Fuglø, Dan

AU - Tangmose, Karen

AU - Kumakura, Yoshitaka

AU - Heltø, Kim

AU - Ebdrup, Bjørn H.

AU - Jensen, Lars Thorbjørn

AU - Rostrup, Egill

AU - Glenthøj, Birte Yding

N1 - Publisher Copyright: © 2021 Society of Biological Psychiatry

PY - 2022

Y1 - 2022

N2 - Background: Dopamine activity has been associated with the response to antipsychotic treatment. Our study used a four-parameter model to test the association between the striatal decarboxylation rate of 18F-DOPA to 18F-dopamine (k3) and the effect of treatment on psychotic symptoms in antipsychotic-naïve patients with first-episode psychosis. We further explored the effect of treatment with a partial dopamine D2 receptor agonist (aripiprazole) on k3 and dopamine synthesis capacity (DSC) determined by the four-parameter model and by the conventional tissue reference method. Methods: Sixty-two individuals (31 patients and 31 control subjects) underwent 18F-DOPA positron emission tomography at baseline, and 15 patients were re-examined after 6 weeks. Clinical re-examinations were completed after 6 weeks (n = 28) and 6 months (n = 15). Symptoms were evaluated with the Positive and Negative Syndrome Scale. Results: High baseline decarboxylation rates (k3) were associated with more positive symptoms at baseline (p < .001) and with symptom improvement after 6 weeks (p = .006). Subregion analyses showed that baseline k3 for the putamen (p = .003) and nucleus accumbens (p = .013) and DSC values for the nucleus accumbens (p = .003) were associated with psychotic symptoms. The tissue reference method yielded no associations between DSC and symptoms or symptom improvement. Neither method revealed any effects of group or treatment on average magnitudes of k3 or DSC, whereas changes in dopamine synthesis were correlated with higher baseline values, implying a potential effect of treatment. Conclusions: Striatal decarboxylation rate at baseline was associated with psychotic symptoms and treatment response. The strong association between k3 and treatment effect potentially implicate on new treatment strategies.

AB - Background: Dopamine activity has been associated with the response to antipsychotic treatment. Our study used a four-parameter model to test the association between the striatal decarboxylation rate of 18F-DOPA to 18F-dopamine (k3) and the effect of treatment on psychotic symptoms in antipsychotic-naïve patients with first-episode psychosis. We further explored the effect of treatment with a partial dopamine D2 receptor agonist (aripiprazole) on k3 and dopamine synthesis capacity (DSC) determined by the four-parameter model and by the conventional tissue reference method. Methods: Sixty-two individuals (31 patients and 31 control subjects) underwent 18F-DOPA positron emission tomography at baseline, and 15 patients were re-examined after 6 weeks. Clinical re-examinations were completed after 6 weeks (n = 28) and 6 months (n = 15). Symptoms were evaluated with the Positive and Negative Syndrome Scale. Results: High baseline decarboxylation rates (k3) were associated with more positive symptoms at baseline (p < .001) and with symptom improvement after 6 weeks (p = .006). Subregion analyses showed that baseline k3 for the putamen (p = .003) and nucleus accumbens (p = .013) and DSC values for the nucleus accumbens (p = .003) were associated with psychotic symptoms. The tissue reference method yielded no associations between DSC and symptoms or symptom improvement. Neither method revealed any effects of group or treatment on average magnitudes of k3 or DSC, whereas changes in dopamine synthesis were correlated with higher baseline values, implying a potential effect of treatment. Conclusions: Striatal decarboxylation rate at baseline was associated with psychotic symptoms and treatment response. The strong association between k3 and treatment effect potentially implicate on new treatment strategies.

KW - Antipsychotic-naïve schizophrenia

KW - Aripiprazole

KW - Dopa decarboxylase

KW - dopamine

KW - Dopamine

KW - F-DOPA

KW - Partial agonist

KW - Positron emission tomography

KW - Psychosis

KW - Striatum

KW - Treatment outcome

U2 - 10.1016/j.biopsych.2021.08.023

DO - 10.1016/j.biopsych.2021.08.023

M3 - Journal article

C2 - 34743917

AN - SCOPUS:85118566303

VL - 91

SP - 236

EP - 245

JO - Biological Psychiatry

JF - Biological Psychiatry

SN - 0006-3223

IS - 2

ER -

ID: 285244864